Powers Principal William von Oehsen was quoted in a Politico article discussing the Trump administration’s decision to cut the drug discount program by more than 28 percent.
The article, titled “Congress Resumes Hearings on Drug Pricing,” discusses how hospitals are challenging the administration’s decision. The American Hospital Association and other organizations are seeking an injunction over the decision to cut the program.
Thirty-two state hospital associations filed a brief in support, stating how devastating the loss of 340B discounts would be. Safety-net providers would be forced to scale back a number of services, including cancer care and HIV programs, according to the article.
In the article, Bill explains how the CMS rule would only affect hospitals covered under 340B, but explained that some of those hospitals operate Ryan White clinics. He said clinics and other providers are worried the move will set a precedent for other payers to cut drug payments on 340B drugs.
To read the full Politico article, click here.
Bill von Oehsen has more than 25 years of experience on pharmaceutical pricing and reimbursement matters, including the 340B drug discount program, the Medicaid drug rebate program, Medicare Part D, Robinson-Patman and state Medicaid and pharmacy laws. He played a key role in helping to enact the 340B program in 1992, as well as to expand the law in 2010 under the Affordable Care Act.
Additionally, Bill has helped to establish and serves as outside counsel to 340B Health, an advocacy organization of more than 1,300 public and private nonprofit hospitals participating in the 340B program. He also helped organize the 340B Coalition, which now represents a dozen national organizations whose members comprise virtually all of the safety net providers participating in the 340B program.